Cellectis SA, the rational genome engineering company and specialist in DNA recombination, announced today that the company has granted AstraZeneca, a worldwide and non-exclusive license under the patent family relating to a process for the specific replacement or insertion of a gene in the receiver genome by homologous recombination.
